scholarly journals PD31-10 STATIN INTAKE REDUCES KIDNEY STONE FORMATION

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Andrew Cohen ◽  
Melanie Adamsky ◽  
Charles Nottingham ◽  
Jaclyn Pruitt ◽  
Brittany Lapin ◽  
...  
2021 ◽  
pp. 105257
Author(s):  
Narjess Bostanghadiri ◽  
Pardis Ziaeefar ◽  
Fatemeh Sameni ◽  
Mohammad Mahmoudi ◽  
Ali Hashemi ◽  
...  

Author(s):  
Raymundo Alejandro Pérez-Hernández ◽  
Silvia Guadalupe Treviño-Moreno ◽  
Gilberto Arévalo- Martínez ◽  
Eduardo Sánchez -García ◽  
Catalina Leos-Rivas ◽  
...  

Background: In clinical therapy, there is no satisfactory drug available for treatment of urolithiasis, especially for the prevention of their recurrence. The aim of this work was to evaluate in vivo antiurolithic activity of methanolic extract of Berberis trifoliata leaves. Material and methods: Urolithiasis was induced in Wistar rats by zinc disc implantation in urinary bladder. Upon postsurgical recovery, different doses of the methanolic extract of B. trifoliata leaves (50, 100 and 150 mg/kg body weight) were administered orally to zinc disc implanted rats for a period of 20 days. Antiurolithiatic activity was evaluated by measuring the difference between the weight of the implanted zinc discs at the time of implantation and the final weight of the dried calculi taken out from the bladder at the end of the 20 days period of treatment. Results: Extract of B. trifoliata significantly reduced calculi deposition around the implanted zinc disc at all doses (50, 100, and 150 mg/kg). Conclusion: Treatment with methanolic extract of B. trifoliata is useful agent against the kidney stone formation.


1994 ◽  
Vol 152 (2 Part 1) ◽  
pp. 324-327 ◽  
Author(s):  
Khashayar Sakhaee ◽  
Sioni Baker ◽  
Joseph Zerwekh ◽  
John Poindexter ◽  
Pedro A. Garcia-Hernandez ◽  
...  

2018 ◽  
Vol 132 (6) ◽  
pp. 615-626 ◽  
Author(s):  
Asokan Devarajan

The prevalence of kidney stones and cardiovascular diseases (CVDs) are increasing throughout the world. Both diseases are chronic and characterized by accumulation of oxidized proteins and lipids in the renal tissue and arterial wall, respectively. Emerging studies have revealed a positive association between nephrolithiasis and CVDs. Based on preclinical and clinical evidences, this review discusses: (i) stone forming risk factors, crystal nucleation, aggregation, injury-induced crystal retention, and stone formation, (ii) CVD risk factors such as dyslipidemia, perturbation of gut microbiome, obesity, free radical-induced lipoprotein oxidation, and retention in the arterial wall, subsequent foam cell formation, and atherosclerosis, (iii) mechanism by which stone forming risk factors such as oxalate, calcium, uric acid, and infection contribute toward CVDs, and (iv) how CVD risk factors, such as cholesterol, phospholipids, and uric acid, contribute to kidney stone formation are described.


Sign in / Sign up

Export Citation Format

Share Document